Brief: China Biotech Services Expected To Record Net Loss Attributable Of About HK$65 Mln For 9M
Oct 31 (Reuters) - China Biotech Services Holdings Ltd
8037.HK :
* GROUP EXPECTED TO RECORD A NET LOSS ATTRIBUTABLE ABOUT
HK$65
MILLION FOR 9M
* EXPECTED RESULT DUE TO DECLINES IN DEMAND FOR GROUP'S
COVID-19
NUCLEIC ACID TESTING SERVICES, AMONG OTHERS
* EXPECTED RESULT DUE TO DECLINES IN DEMAND FOR GROUP'S
COVID-19
NUCLEIC ACID TESTING SERVICES
Source text for Eikon: ID:
Further company coverage: 8037.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on China Biotech Services Holdings
See all newsBrief: China Biotech Services Enters Cooperation Agreement
Brief: China Biotech Services Says HY Revenue From Cont Ops Hk$37.23 Million
Brief: China Biotech Services Expects HY Net Profit Of Not Less Than HK$15.0 MLN
Brief: China Biotech Services Enters Master Collaboration Agreement With Stella Pharma
Brief: China Biotech Services Says BGI Songhe Advances RMB30 Million Loan To Pengbo (Hainan)